Shares in Stoke Therapeutics (Nasdaq: STOK) have fallen by a third after the company announced what it described as “positive new safety and efficacy data” from its early stage trial program for STK-001.
The company’s lead candidate is an antisense oligonucleotide, under development for the rare and serious condition known as Dravet syndrome.
The Massachusetts, USA-based firm believes STK-001 has the potential to be the first disease-modifying therapy to address the genetic causes of the disorder, which results in severe and progressive fits of epilepsy.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze